Table 2 Sensitivity analyses of the HER2DX risk score for RFS and OS in the overall cohort and in the node-negative subgroup
Outcome | Group | Time (yrs) | Low-risk estimate (95% CI) | High-risk estimate (95% CI) | HR (95% CI) |
|---|---|---|---|---|---|
RFS | All patients | 5 | 91.7 (86.7–97.1) | 77.2 (65.1–91.5) | 0.35 (0.1–0.9) |
6 | 88.6 (82.7–94.9) | 74.2 (61.6–89.4) | 0.41 (0.2–0.9) | ||
7 | 86.5 (80.1–93.4) | 68.0 (54.4–85.0) | 0.38 (0.2–0.8) | ||
8 | 86.5 (80.1–93.4) | 68.0 (54.4–85.0) | 0.38 (0.2–0.8) | ||
9 | 83.7 (76.6–91.5) | 68.0 (54.4–85.0) | 0.43 (0.2–0.9) | ||
10 | 81.2 (72.9–90.4) | 68.0 (54.4–85.0) | 0.46 (0.2–1.0) | ||
Node-negative | 5 | 91.4 (86.2–96.9) | 72.6 (54.6–96.4) | 0.30 (0.1–0.9) | |
6 | 89.2 (83.4–95.2) | 72.6 (54.6–96.4) | 0.36 (0.1–1.0) | ||
7 | 87.0 (80.7–93.9) | 58.6 (38.9–88.4) | 0.28 (0.1–0.7) | ||
8 | 87.0 (80.7–93.9) | 58.6 (38.9–88.4) | 0.28 (0.1–0.7) | ||
9 | 84.1 (76.8–92.0) | 58.6 (38.9–88.4) | 0.31 (0.1–0.8) | ||
10 | 81.4 (72.8–90.9) | 58.6 (38.9–88.4) | 0.32 (0.1–0.8) | ||
OS | All patients | 5 | 97.3 (94.4–100) | 83.9 (72.9–96.6) | 0.17 (0.0–0.7) |
6 | 95.4 (91.6–99.4) | 80.8 (68.9–94.8) | 0.23 (0.1–0.7) | ||
7 | 93.5 (88.9–98.3) | 74.3 (61.1–90.5) | 0.23 (0.1–0.6) | ||
8 | 93.5 (88.9–98.3) | 74.3 (61.1–90.5) | 0.23 (0.1–0.6) | ||
9 | 90.9 (85.4–96.9) | 74.3 (61.1–90.5) | 0.29 (0.1–0.7) | ||
10 | 88.7 (81.5–96.1) | 69.7 (55.2–88.1) | 0.30 (0.1–0.7) | ||
Node-negative | 5 | 97.2 (93.4–100) | 72.2 (59.7–99.8) | 0.12 (0.0–0.5) | |
6 | 95.2 (91.3–99.6) | 70.8 (57.5–99.9) | 0.19 (0.0–0.9) | ||
7 | 94.2 (89.8–98.8) | 63.7 (43.9–92.3) | 0.14 (0.0–0.4) | ||
8 | 94.2 (89.8–98.8) | 63.7 (43.9–92.3) | 0.14 (0.0–0.4) | ||
9 | 91.6 (86.0–97.5) | 63.7 (43.9–92.3) | 0.18 (0.1–0.5) | ||
10 | 89.2 (82.3–96.7) | 47.7 (24.3–93.9) | 0.16 (0.1–0.4) |
